Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Xspray Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2022
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Xspray Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Hematology
Study Phase : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 28, 2020
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Hematology
Highest Development Status : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 04, 2019
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amphotericin B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Aurobindo Pharma Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2018
Lead Product(s) : Amphotericin B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Aurobindo Pharma Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 12, 2016
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 10, 2016
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 03, 2015
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2014
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Acrotech Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable